SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Commission file number: 001-38428
(Translation of registrant’s name into English)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
On November 7, 2023, PolyPid Ltd. (the “Company”) announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors (the “Board”), effective November 6, 2023, as well as the retirement of Ms. Anat Tsour Segal from the Board.
Dr. Tweezer-Zaks, age 58, has served as Chief Executive Officer of MediCane Health Inc., a fully integrated global medical cannabis company, since July 2022, where she leads all strategic, operational, scientific and development activities. She previously served as Chief Medical Officer and Business Development of MediCane Health Inc. from April 2021 to July 2022. Dr. Tweezer-Zaks served as Chief Medical Officer of aMOON Venture Capital Fund (“aMOON”), a leading Israel-based life sciences-focused venture capital investor, from May 2020 to April 2021, and as Operating Partner and Head of Sourcing from June 2018 April 2020 at aMOON. Prior to this, Dr. Tweezer-Zaks held increasingly senior positions at Sanofi. In her most recent role at Sanofi from June 2017 to June 2018, she served as Global Established Products Medical Lead – Strategic Decision for Portfolio Enhancement. Dr. Tweezer-Zaks holds M.D. and B.S. degrees from Ben Gurion University School of Medicine in Beer Sheva, Israel, and earned an M.B.A. from the Kellogg-Recanati International Executive MBA Program, a global partnership program between Northwestern University’s Kellogg School of Management in Evanston, IL, and Tel Aviv University’s Recanati Graduate School of Business Administration in Israel.
The Board concluded that Dr. Tweezer-Zaks is qualified to serve as a Director and is independent under the rules of the Nasdaq Stock Market. For her service as a Director, Dr. Tweezer-Zaks will be entitled to the compensation the Company generally provides to its Directors. The Company expects to enter into its standard indemnification agreement with Dr. Tweezer-Zaks, on substantially the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. Dr. Tweezer-Zaks is not a party to any transactions that are disclosable under Item 7.B of Form 20-F.
The Company’s press release dated November 7, 2023, announcing Dr. Tweezer-Zaks’ appointment is attached hereto as Exhibit 99.1.
The Report on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-257651) and Form S-8 (File No. 333-239517 and File No. 333-271060), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
|99.1||Press release titled: “PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors.”|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: November 7, 2023||By:||/s/ Dikla Czaczkes Akselbrad|
|Name:||Dikla Czaczkes Akselbrad|
|Title:||Chief Executive Officer|
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal
PETACH TIKVA, Israel, November 7, 2023 (GLOBE NEWSWIRE) – PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years.
“We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physician, biopharmaceutical industry executive and sector investor,” said Jacob Harel, PolyPid’s Chairman. “We look forward to leveraging Dr. Tweezer-Zaks’ vast expertise across the business development, clinical, R&D, and financial functions as we approach critical clinical and regulatory milestones, as well as potential commercialization, of our late-stage product candidate, D-PLEX100 for the prevention of surgical site infections (“SSIs”). I would also like to thank Anat for her distinguished service and counsel as a member of PolyPid’s Board since April 2008. She has been instrumental in the Company’s evolution to a fully integrated biopharmaceutical company.”
Dr. Tweezer-Zaks said, “I am excited to be joining the PolyPid Board at this important time for the company. I believe that D-PLEX100 has the potential to significantly improve patient surgical outcomes and reduce the substantial burden on the healthcare system that SSIs pose. I look forward to working collaboratively with the Board and the management team to best position PolyPid for success as we approach potential approval and commercialization.”
Anat Tsour Segal said, “I feel privileged and honored to have served PolyPid for the past 15 years from its very inception. PolyPid brings a transformational and vital technology to the world, that has the potential to make a real difference in the prevention of post-surgical infections as well as in other areas where slow, local, controlled drug delivery is effective. I wish to thank the Board and the team for 15 wonderful years, and I wish the Company much success.”
Dr. Tweezer-Zaks currently serves as Chief Executive Officer of MediCane Health, a fully-integrated global medical cannabis company. Previously, Dr. Tweezer-Zaks served in increasingly senior positions at aMOON, a leading Israel-based life sciences-focused venture capital investor. In her most recent role as Chief Medical Officer at aMOON, she managed the internal and external interfaces across the fund between investors, portfolio companies, and investment teams, and provided professional input to the investment committee. Prior to this, Dr. Tweezer-Zaks held increasingly senior positions at Sanofi. In her most recent role at Sanofi, she served as Global Established Products Medical Lead – Strategic Decision for Portfolio Enhancement. In this role Dr. Tweezer-Zaks focused on life cycle management of portfolio products. She began her career as a practicing internal medicine physician at Sheba Medical Center in Israel.
Dr. Tweezer-Zaks has authored numerous scientific publications. She holds M.D. and B.S. degrees from Ben-Gurion University School of Medicine in Beer Sheva, Israel, and earned an M.B.A. from the Kellogg-Recanati International Executive MBA Program, a global partnership program between Northwestern University’s Kellogg School of Management in Evanston, IL, and Tel Aviv University’s Recanati Graduate School of Business Administration in Israel.
D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX100 received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX100 is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing open abdominal colorectal surgery with large incisions.
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses potential approval and commercializing of D-PLEX100 and D-PLEX100 potential to significantly improve patient surgical outcomes and reduce the substantial burden on the healthcare system that SSIs pose. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on March 31, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
COO – US